Watermark
  Back to Search Results

BGB-A317-306

Completed

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-306

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT03783442

EudraCT or EUCT Number Info icon SVG graphic used for tooltips or additional information.

2018-000587-28

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20181013

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan Plain Language Summary

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan Plain Language Summary